In vitro chemosensitivity test of malignant gliomas: clinical relevance of test results independent of adjuvant chemotherapy

Tumor specimens of malignant human gliomas were processed in a colony forming assay (CFA, n = 70) and a metabolic test system (MTT-test, n = 49) for in-vitro chemosensitivity testing. The clinical data as well as the complete follow-up of these patients were obtained until their death or at least 2...

Full description

Saved in:
Bibliographic Details
Published inAnticancer research Vol. 14; no. 3B; p. 1371
Main Authors Tonn, J C, Schachenmayr, W, Kraemer, H P
Format Journal Article
LanguageEnglish
Published Greece 01.05.1994
Subjects
Carmustine - pharmacology
Carmustine - therapeutic use
Female
Glioma - drug therapy
Glioma - mortality
Glioma - pathology
Humans
Male
Middle Aged
Nimustine - pharmacology
Nimustine - therapeutic use
Survival Rate
Tumor Stem Cell Assay
Online AccessGet more information

Cover

More Information
Summary:Tumor specimens of malignant human gliomas were processed in a colony forming assay (CFA, n = 70) and a metabolic test system (MTT-test, n = 49) for in-vitro chemosensitivity testing. The clinical data as well as the complete follow-up of these patients were obtained until their death or at least 2 years of survival. By means of multivariate statistical analysis we demonstrate that both test systems are not influenced by biometrical data of the patient of histopathological parameters of the tumor. According to the COX regression model the results of both assays are per se no prognostic factor when regarded independently of additional treatment. However, in 33 patients treated with either ACNU or BCNU, a prospective correlative trial clearly demonstrates a predictive value of the CFA in adjuvant chemotherapy of gliomas.
ISSN:0250-7005